New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
06:22 EDTINCYIncyte price target raised to $75 from $44 at Jefferies
Jefferies raised its price target for Incyte shares to $75 from $44 on expectations the company's IDO inhibitor with ipilimumab for melanoma could "unlock huge value." The firm says it heard positive commentary from four investigators involved in the Phase 2 study and keeps a Buy rating on the stock.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 18, 2015
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use